Drug intelligence / Profile preview

RCT1311

Development stage: Preclinical
Lead developer: ReCerise Therapeutics
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

RCT1311 is a preclinical-stage multi-specific antibody being developed by ReCerise Therapeutics for the treatment of solid cancers, with a specific focus on pancreatic ductal adenocarcinoma (PDAC) and other biliary or gastrointestinal cancers (OBC). As a multi-specific therapeutic, it is engineered to simultaneously target multiple antigens or signaling pathways involved in tumor progression and immune evasion. The drug is part of ReCerise's pipeline focusing on difficult-to-treat gastrointestinal malignancies and is currently undergoing preclinical evaluation.

Beyond the preview

Go deeper on RCT1311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCT1311.

Explore the full profile